New -Mab Cuts Sickle cell crises in Half

Antibody biologic administered 14 infusions cut sickle cell crises from 2.98/yr to 1.63/year.

Ataga, Kenneth I., et al.
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
New England Journal of Medicine (2016) in press

  • 198 cases – high-dose crizanlizumab (5.0 mg per kilogram), or placebo
  •  14 times over a period of 52 weeks
  • high-dose crizanlizumab – median rate of crises per year was 1.63
    placebo – 2.98 ( a 45.3% lower rate with high-dose crizanlizumab, P=0.01)
  • “Adverse events that occurred in 10% or more of the patients in either active-treatment group and at a frequency that was at least twice as high as that in the placebo group were arthralgia, diarrhea, pruritus, vomiting, and chest pain.”

Comment – disappointing it wasn’t better considering so many infusions and probably considerable cost but at least something bijoux pandora bijoux pandora

This entry was posted in sickle crisis. Bookmark the permalink.

Leave a Reply

Your email address will not be published.